Although subarachnoid haemorrhage is more common among women than they are among men, the reasons for this difference were unclear. While smoking is the main risk factor, this study examined the association between smoking habits and subarachnoid haemorrhage in a large prospective study.
Cefaly has announced that its eponymous Cefaly device—which is a US Food and Drug Administration (FDA)-approved external trigeminal nerve stimulation device for the prevention of frequent episodic migraine attacks—has been revamped.
Penumbra has launched its new ACE 68 reperfusion catheter in the USA. The catheter is part of the Penumbra System, and was launched at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting in Boston, USA.
Hypertension remains the single most important modifiable risk factor for stroke, and the impact of hypertension and nine other risk factors together account for 90% of all strokes, according to an analysis of nearly 27000 people from every continent in the world (INTERSTROKE), published in The Lancet.
Penumbra has announced its schedule of key events at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting (July 25-28 2016, Boston, USA). These events include the presentation of the results of the randomised controlled clinical trial for the company’s next generation stent retriever, the Penumbra 3D revascularisation device.
Mentice has received a grant from the Swedish government agency for innovation, Vinnova, to develop a simulation-based training system including validated metrics capable of assessing proficiency in treatment of acute ischaemic stroke.
The Contour Neurovascular System (Cerus Endovascular) will offer a new option for treating intracranial aneurysms. According to Kyriakos Lobotesis, Principle Clinical Advisor at Cerus, “the objective of the device is to treat the neck of the aneurysm, thus avoiding protracted manoeuvres and manipulation within the aneurysm, which can be experienced while using other available devices”.
A study of the long-term use of the ADAPT technique for the treatment of acute ischaemic stroke has confirmed that it is an efficient method to achieve good clinical and angiographic outcomes, with 82.2% of patients achieving TICI 2C or better recanalisation and 90-day mRS scores of 0–2 in 54.4%.
A cohort study has found that medical devices approved first in the European Union (EU) are associated with a greater rate of post-marketing safety alerts and recalls compared with devices approved first in the USA.
Two peer-reviewed studies recently published in Neurosurgery and Operative Neurosurgery have shown statistically significant data in favour of the BrainPath approach (NICO), citing more than 95% clot reduction, the ability to walk in 94% of patients (mRS 0-3 at 30-365 days), and no mortalities in one study with patient groups suffering from haemorrhagic stroke.
Air pollution—including environmental and household air pollution—has emerged as a leading risk factor for stroke worldwide, associated with about a third of the global burden of stroke in 2013, according to a new study published in The Lancet Neurology journal.
The US Food and Drug Administration has approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication. ExAblate Neuro from Insightec uses magnetic resonance (MR) images taken during the procedure to deliver focused ultrasound to destroy brain tissue in a tiny area thought to be responsible for causing tremors.
The World Stroke Organization has announced a global partnership with Medtronic to increase stroke awareness through several initiatives.
Mobile devices, social media, visual media and crowdsourcing have the potential to improve emergency care for cardiac arrests, heart attacks and strokes, according to a new scientific statement from the American Heart Association.
Blue Cross Blue Shield has denied coverage for high frequency [10,000 (HF10)] spinal cord stimulation in at least two states. Outposts of the federation of health insurance organisations in Tennessee and Pennsylvania (both USA) consider HF10 spinal cord stimulation to be experimental and investigational for the treatment of leg and back pain.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos